Mixed treatment comparison of prophylaxis against invasive fungal infections in neutropenic patients receiving therapy for haematological malignancies: A systematic review

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 1, 2014, Pages 1-11

  Pechlivanoglou, Petros ^a,b   Le, Hoa H ^b   Daenen, Simon ^c   Snowden, John A ^d,e   Postma, Maarten J ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^e UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Antifungals; Evidence synthesis; IFIs

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; FLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; PLACEBO; POSACONAZOLE; VORICONAZOLE;

ASPERGILLOSIS; CANDIDIASIS; CAUSE OF DEATH; DRUG EFFICACY; HEMATOLOGIC MALIGNANCY; HUMAN; INFECTION PREVENTION; INFECTION RISK; MORTALITY; NEUTROPENIA; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SYSTEMATIC REVIEW; SYSTEMIC MYCOSIS; TREATMENT OUTCOME;

ANTIFUNGALS; EVIDENCE SYNTHESIS; IFIS;

ANTIFUNGAL AGENTS; CHEMOPREVENTION; HEMATOLOGIC NEOPLASMS; HUMANS; MYCOSES; NEUTROPENIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SURVIVAL ANALYSIS;

EID: 84890368204     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt329     Document Type: Review

References (62)

1. Goodrich JM, Reed EC, Mori M et al. Clinical features and analysis of risk factors for invasive candidal infection after marrow transplantation. J Infect Dis 1991; 164: 731-40.
2. Prentice HG, Kibbler CC, Prentice AG. Towards a targeted, risk-based, antifungal strategyinneutropenicpatients. Br JHaematol2000;110:273-84.
3. Pagano L, Caira M, Nosari A et al. Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study-Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. Clin Infect Dis 2007; 45: 1161-70.
4. Pagano L, Caira M, Candoni A et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 2006; 91: 1068-75.
5. Nosari A, Barberis M, Landonio G et al. Infections in haematologic neoplasms: autopsy findings. Haematologica 1991; 76: 135-40.
6. Martino R, Subira M. Invasive fungal infections in hematology: new trends. Ann Hematol 2002; 81: 233-43.
7. Hamza NS, Ghannoum MA, Lazarus HM. Choices aplenty: antifungal prophylaxis in hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2004; 34: 377-89.
8. Pfaller MA, DiekemaDJ. Epidemiologyof invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007; 20: 133-63.
9. Playford EG, Marriott D, Nguyen Q et al. Candidemia in nonneutropenic critically ill patients: risk factors for non-albicans Candida spp. Crit Care Med 2008; 36: 2034-9.
10. Viscoli C, Girmenia C, Marinus A et al. Candidemia in cancer patients: a prospective, multicenter surveillance study by the invasive fungal infection group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 1999; 28: 1071-9.
11. Garcia-Vidal C, Upton A, Kirby KA et al. Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation. Clin Infect Dis 2008; 47: 1041-50.
12. Marr KA, Carter RA, Crippa F et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34: 909-17.
13. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001; 32: 358-66.
14. Upton A, Kirby KA, Carpenter P et al. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis 2007; 44: 531-40.
15. Erjavec Z, Kluin-Nelemans H, Verweij PE. Trends in invasive fungal infections, with emphasis on invasive aspergillosis. Clin Microbiol Infect 2009; 15: 625-33.
16. van Burik JA. Role of newantifungal agents in prophylaxis ofmycoses in high risk patients. Curr Opin Infect Dis 2005; 18: 479-83.
17. Maertens J, Buve K, Anaissie E. Broad-spectrum antifungal prophylaxis in patients with cancer at high risk for invasive mold infections: counterpoint. J Natl Compr Canc Netw 2008; 6: 183-9.
18. Pagano L, Caira M, Valentini CG et al. Current therapeutic approaches to fungal infections in immunocompromised hematological patients. Blood Rev 2010; 24: 51-61.
19. Cornely OA, Maertens J, Winston DJ et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. NEngl J Med 2007; 356: 348-59.
20. Wingard JR, Carter SL, Walsh TJ et al. Randomized double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection (IFI) after allogeneic transplantation. Blood 2010; 116: 5111-8.
21. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004; 23: 3105-24.
22. Jansen JP, Crawford B, Bergman G et al. Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons. Value Health 2008; 11: 956.
23. Higgins J, Green S (eds). Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration. Available from www. cochrane-handbook.org, 2011 (6 August 2013, date last accessed).
24. Cornely OA, Bohme A, Buchheidt D et al. Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. Haematologica 2009; 94: 113-22.
25. Marr KA, Carter RA, Boeckh M et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002; 100: 4358-66.
26. Jantunen E, Ruutu P, Niskanen L et al. Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients. Bone Marrow Transplant 1997; 19: 801-8.
27. Boogaerts M, Maertens J. Clinical experience with itraconazole in systemic fungal infections. Drugs 2001; 61 Suppl 1: 39-47.
28. Trifilio S. Update on antifungal drug dosing and therapeutic drug monitoring. Curr Fungal Infect Rep 2011; 5: 92-102.
29. Cooper NJ, Sutton AJ, Morris D et al. Addressing between-study heterogeneity and inconsistency in mixed treatment comparisons: application to stroke prevention treatments in individuals with non-rheumatic atrial fibrillation. Stat Med 2009; 28: 1861-81.
30. Cooper NJ, Sutton AJ, Lu G et al. Mixed comparison of stroke prevention treatments in individuals with nonrheumatic atrial fibrillation. Arch Intern Med 2006; 166: 1269-75.
31. Spiegelhalter DJ, Best NG, Carlin BP et al. Bayesian measures of model complexity and fit. J R Stat Soc Ser B Stat Methodol 2002; 64: 583-639.
32. Salanti G, Higgins JP, Ades AE et al. Evaluation of networks of randomized trials. Stat Methods Med Res 2008; 17: 279-301.
33. Gelman A, Carlin J, Stern H et al. Bayesian Data Analysis. Boca Raton, FL: Chapman & Hall/CRC, 2003.
34. Lunn D, Thomas A, Best N et al. WinBUGS-a Bayesian modelling framework: concepts, structure, and extensibility. Stat Comput 2000; 10: 325-37.
35. Carrigan G, Barnett AG, Dobson AJ et al. Compensating for missing data from longitudinal studies using WinBUGS. J Stat Soft 2007; 19: 1-17.
36. Winston DJ, Chandrasekar PH, LazarusHMet al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia: results of arandomized placebo-controlled, double-blind, multicenter trial. Ann Intern Med 1993; 118: 495-503.
37. Tollemar J, Ringden O, Andersson S et al. Randomized double-blind study of liposomal amphotericin B (Ambisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients. Bone Marrow Transplant 1993; 12: 577-82.
38. Vreugdenhil G, Van Dijke BJ, Donnelly JP et al. Efficacy of itraconazole in the prevention of fungal infections among neutropenic patients with hematologic malignancies and intensive chemotherapy. A double blind, placebo controlled study. Leuk Lymphoma 1993; 11: 353-8.
39. Winston DJ, Maziarz RT, Chandrasekar PH et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients: a multicenter, randomized trial. Ann Intern Med 2003; 138: 705-13.
40. Schaffner A, Schaffner M. Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use, and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasias. J Infect Dis 1995; 172: 1035-41.
41. Slavin MA, Osborne B, Adams R et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation: a prospective, randomized, double-blind study. J Infect Dis 1995; 171: 1545-52.
42. Kelsey SM, Goldman JM, McCann S et al. Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study. Bone Marrow Transplant 1999; 23: 163-8.
43. Menichetti F, Favero AD, Martino P et al. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche dell' Adulto. Clin Infect Dis 1999; 28: 250-5.
44. Morgenstern GR, Prentice AG, PrenticeHGet al. Arandomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. Br J Haematol 1999; 105: 901-11.
45. Rotstein C, Bow EJ, Laverdiere M et al. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. Clin Infect Dis 1999; 28: 331-40.
46. Nucci M, Biasoli I, Akiti T et al. A double-blind, randomized, placebo-controlled trial of itraconazole capsules as antifungal prophylaxis for neutropenic patients. Clin Infect Dis 2000; 30: 300-5.
47. Glasmacher A, Cornely O, Ullmann AJ et al. An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia. J Antimicrob Chemother 2006; 57: 317-25.
48. Mattiuzzi GN, Alvarado G, Giles FJ et al. Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies. Antimicrob Agents Chemother 2006; 50: 143-7.
49. Mattiuzzi G, Cortes J, Alvarado G et al. Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome. Support Care Cancer 2011; 19: 19-26.
50. Oren I, Rowe JM, Sprecher H et al. A prospective randomized trial of itraconazole vs fluconazole for the prevention of fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2006; 38: 127-34.
51. Penack O, Schwartz S, Martus P et al. Low-dose liposomal amphotericin B in the prevention of invasive fungal infections in patients with prolonged neutropenia: results from a randomized, single-center trial. Ann Oncol 2006; 17: 1306-12.
52. Hiramatsu Y, Maeda Y, FujiiNet al. Use of micafungin versus fluconazole for antifungal prophylaxis in neutropenic patients receiving hematopoietic stem cell transplantation. Int J Hematol 2008; 88: 588-95.
53. Marks DI, Pagliuca A, Kibbler CC et al. Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation. Br J Haematol 2011.
54. Goodman JL, Winston DJ, Greenfield RA et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326: 845-51.
55. Annaloro C, Oriana A, Tagliaferri E et al. Efficacy of different prophylactic antifungal regimens in bonemarrowtransplantation. Haematologica 1995; 80: 512-7.
56. Ito Y, Ohyashiki K, Yoshida I et al. The prophylactic effect of itraconazole capsulesandfluconazole capsules for systemic fungal infections inpatients with acutemyeloid leukemia andmyelodysplastic syndromes: a Japanese multicenter randomized, controlled study. Int J Hematol 2007; 85: 121-7.
57. Yamac K, Senol E, Haznedar R. Prophylactic use of fluconazole in neutropenic cancer patients. Postgrad Med J 1995; 71: 284-6.
58. Choi SM, Lee DG, Choi JH et al. Itraconazole oral solution versus fluconazole syrup for prevention of invasive fungal infections in patients receiving hematopoietic stem cell transplantation: prospective, randomized, comparative clinical trial. Infect Chemother 2005; 37: 71-8.
59. Freifeld AG, Bow EJ, Sepkowitz KA et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011; 52: e56-93.
60. Robenshtok E, Gafter-Gvili A, Goldberg E et al. Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis. J Clin Oncol 2007; 25: 5471-89.
61. Mikolajewska A, Schwartz S, RuhnkeM. Antifungal treatment strategies in patients with haematological diseases or cancer: from prophylaxis to empirical, pre-emptive and targeted therapy. Mycoses 2012; 55: 2-16.
62. Rogers TR, Slavin MA, Donnelly JP. Antifungal prophylaxis during treatment for haematological malignancies: are we there yet?. Br J Haematol 2011; 153: 681-97.